3-fluoro-N-isopropylbenzene-1,2-diamine | 1033010-33-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-fluoro-N-isopropylbenzene-1,2-diamine
• 英文别名: 3-fluoro-1-N-(propan-2-yl)benzene-1,2-diamine；3-fluoro-1-N-propan-2-ylbenzene-1,2-diamine
• CAS: 1033010-33-1
• 化学式: C₉H₁₃FN₂
• mdl: MFCD12149481
• 分子量: 168.214
• InChiKey: MWTDLGUALTZRCA-UHFFFAOYSA-N

物化性质

• 沸点：
  260.9±30.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-fluoro-N-isopropylbenzene-1,2-diamine 、 N,N'-羰基二咪唑 以 四氢呋喃 为溶剂， 生成 4-fluoro-1-isopropyl-1,3-dihydro-benzimidazol-2-one
  参考文献：
  名称：

  新型1-或3-（3-氨基-1-苯基丙基）-1,3-二氢-2H-苯并咪唑-2-酮作为选择性去甲肾上腺素再摄取抑制剂的合成及活性。

  摘要：

  发现了一系列新型的1-或3-（3-氨基-1-苯基丙基）-1,3-二氢-2H-苯并咪唑-2-酮作为选择性去甲肾上腺素再摄取抑制剂。几种化合物（例如15和20）显示出良好的hNET效力。化合物15和20在hNET上也表现出优异的选择性，似乎优于瑞波西汀和阿托西汀（4和5）。

  DOI：

  10.1016/j.bmcl.2008.10.026
• 作为产物：
  描述：

  (3-fluoro-2-nitro-phenyl)-isopropyl-amine 在 sodium tetrahydroborate 、 5% Pd(II)/C(eggshell) 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-fluoro-N-isopropylbenzene-1,2-diamine
  参考文献：
  名称：

  1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors

  摘要：

  Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). In general, this series of compounds potently blocked the human norepinephrine transporter (hNET) while exhibiting selectivity at hNET against both the human serotonin (hSERT) and dopamine transporters (hDAT). Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC(50) values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT. Several compounds, such as 20 and 22, were tested in a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction and were efficacious at oral doses of 3 mg/kg in reducing the tail skin temperature. In addition, compound 20 was also studied in the rat hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain, respectively, and was orally efficacious at doses of 3-10 mg/kg.

  DOI：

  10.1021/jm900888c

文献信息

• Organic compounds
  申请人：Glatthar Ralf

  公开号：US20090105266A1

  公开（公告）日：2009-04-23

  The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the formula (I): in which the substitutents are as defined in claim 1 and salts, solvates, hydrates and N-oxides thereof.

  本发明涉及新型苯并咪唑衍生物，其制备，其用作药物以及含有它们的药物组合物，其中化合物具有以下结构式（I）： 其中取代基如权利要求1中所定义，并且其盐、溶剂合物、水合物和N-氧化物。
• DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE
  申请人：Zhang Puwen

  公开号：US20080153873A1

  公开（公告）日：2008-06-26

  The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

  本发明涉及具有以下结构的二氢苯并呋喃基衍生物：或其药用盐，这些衍生物是单胺再摄取抑制剂，含有这些衍生物的组合物，以及它们用于预防和治疗条件的方法，包括但不限于血管运动症状性功能障碍、胃肠道紊乱和泌尿系统紊乱、抑郁症、内源性行为障碍、认知障碍、糖尿病性神经病变、疼痛和其他疾病或障碍。
• NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
  申请人：Novartis AG

  公开号：EP2146969A1

  公开（公告）日：2010-01-27
• [EN] DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DÉRIVÉS DIHYDROBENZOFURANYLES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：WYETH CORP

  公开号：WO2008073943A1

  公开（公告）日：2008-06-19

  [EN] The present invention is directed to dihydrobenzofuranyl derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and Other diseases or disorders.
  [FR] La présente invention concerne des dérivés dihydrobenzofuranyles de formule (I), ou un sel pharmaceutiquement acceptable de ceux-ci, qui sont des inhibiteurs de recaptage des monoamines, des compositions contenant ces dérivés, et leurs procédés d'utilisation pour la prévention et le traitement de conditions comprenant, entre autres, les symptômes vasomoteurs, de dysfonctionnement sexuel, les troubles gastro-intestinaux, le trouble génito-urinaire, les troubles dépressifs, le trouble du comportement endogène, le trouble cognitif, la neuropathie diabétique, et d'autres maladies ou troubles.
• [EN] NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2008128968A1

  公开（公告）日：2008-10-30

  [EN] The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the Formula (I): in which the substitutents are as defined in claim 1 and and salts, solvates, hydrates and N- oxides thereof.
  [FR] La présente invention concerne de nouveaux dévirés de benzimidazole, leur préparation, leur utilisation en tant que produits pharmaceutiques et des compositions pharmaceutiques les contenant, les composés étant de formule (I) : dans laquelle les substituants sont tels que définis dans la revendication 1 et les sels, solvates, hydrates et N-oxydes de ceux-ci.